Clinical trial NCT03335267: Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Official title: Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Leukemia, Myeloid, Acute
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
Collaborators: name: Jazz Pharmaceuticals
First posted: 2017-11-07
Enrollment: 30
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label study to assess the suitability of CPX-351 as first intensive therapy in elderly (age ≥60 years) patients with AML. Patients may have received prior AML treatment with non-intensive regimens, e.g. hypomethylating agents, low dose Ara C or lenolidomide, but may not have received intensive AML treatment with anthracyclines and/or cytarabine prior to enrollment on this trial. The outcome of elderly patients following intensive treatment with CPX-351 will be measured by clinical endpoints for efficacy and safety and by biological/functional response.


Eligibility criteria: Inclusion Criteria:

* Ability to understand and voluntarily give informed consent
* Age≥60 years at the time of study treatment
* Pathological diagnosis of AML according to WHO criteria (with \>20% blasts in the peripheral blood or bone marrow) including:
* De novo AML with normal karyotype or adverse karyotypes (including patients with karyotypic abnormalities characteristic of MDS)
* Secondary AML: transformed from prior MDS or MPN, confirmed by bone marrow documentation of prior antecedent hematologic disorder
* Therapy-related AML: t-AML, requires documented history of prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease
* Performance status \>50% KPS, ECOG 0-2
* Laboratory values fulfilling the following:
* Serum creatinine \< 2.5 mg/dL
* Serum total bilirubin \< 2.5 mg/dL,
* Serum alanine aminotransferase or aspartate aminotransferase \< 3 times the ULN
* Patients with elevated liver enzymes and serum creatinine values secondary to AML are eligible after discussion with PI
* Cardiac ejection fraction ≥ 50% by echocardiography or MUGA
* Patients with history of second malignancies in remission may be eligible if there is clinical evidence of disease stability off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible.

Exclusion Criteria:

* Acute promyelocytic leukemia \[t(15;17)\]
* Clinical evidence of active CNS leukemia
* Prior intensive chemotherapy for AML with anthracycline/cytarabine-based regimens and/ or prior HSCT. Patients may have been treated with commercially available or investigational hypomethylating agents (e.g. decitabine, azacitidine, SGI-110), lenalidomide, or low-dose cytarabine (not to exceed 20 mg/m2 daily for 14 days for ≤ 6 cycles)
* Prior treatment including HMA, systemic chemotherapy, surgery, or radiation therapy must have been completed at least 7 days before start of study treatment or after discussion with PI. Treatment with investigational agents must have been completed at least 14 days prior to study drug treatment. Hydroxyurea is permitted for control of blood counts before the start of study treatment. Toxicities associated with prior therapies must have recovered to grade 1 or less prior to start of study treatment.
* Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).
* Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent
* Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging)
* Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥72 hrs.
* Patients with current or recent evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible
* Known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values)
* Hypersensitivity to cytarabine, daunorubicin or liposomal products
* History of Wilson's disease or other copper-metabolism disorder
* History of prior bone marrow or solid organ transplantation

Primary outcomes:
measure: Primary Efficacy
timeFrame: 2.5 Years
measure: 30-Day Mortality Rate
timeFrame: 30 Days
Secondary outcomes:
measure: Complete Response Rate (CR, CRp, CRi, and CR+CRp+CRi)
timeFrame: 30 days post-treatment, up to 3 months post-baseline
measure: Change in Relationship of Cognitive Function to Treatment Response and OS, Event-free Survival and Morphologic Leukemia Free State as Measured by the MOCA
timeFrame: Screening through 30 days post-treatment, up to 3 months post-baseline
measure: Change in Relationship of Cognitive Function to Treatment Response and OS, Event-free Survival and Morphologic Leukemia Free State as Measured by the Blessed Orientation-Memory-Concentration Test
timeFrame: Screening through 30 days post-treatment, up to 3 months post-baseline
measure: Incidence of Adverse Events
timeFrame: Through treatment completion, an average of 1 year
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Ellen K Ritchie, MD
role: PRINCIPAL_INVESTIGATOR
References: